PortfoliosLab logoPortfoliosLab logo
SBIO vs. XLVI
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

SBIO vs. XLVI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ALPS Medical Breakthroughs ETF (SBIO) and State Street Health Care Select Sector SPDR Premium Income ETF (XLVI). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, SBIO achieves a 1.95% return, which is significantly higher than XLVI's 1.35% return.


SBIO

1D
2.35%
1M
-5.55%
YTD
1.95%
6M
4.13%
1Y
68.86%
3Y*
18.38%
5Y*
3.16%
10Y*
8.03%

XLVI

1D
2.03%
1M
4.01%
YTD
1.35%
6M
3.19%
1Y
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

SBIO vs. XLVI - Yearly Performance Comparison


Correlation

The correlation between SBIO and XLVI is 0.45, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (All Time)
Calculated using the full available price history since Jul 31, 2025

0.45

SBIO vs. XLVI - Sectors Allocation Comparison


Sectors
SBIO
XLVI

Healthcare

100.0%

-

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Industrials

-

-

Real Estate

-

-

Technology

-

-

Utilities

-

-

Financial Services

-0.0%
100.6%

Healthcare

SBIO
100.0%
XLVI

-

Basic Materials

SBIO

-

XLVI

-

Communication Services

SBIO

-

XLVI

-

Consumer Cyclical

SBIO

-

XLVI

-

Consumer Defensive

SBIO

-

XLVI

-

Energy

SBIO

-

XLVI

-

Industrials

SBIO

-

XLVI

-

Real Estate

SBIO

-

XLVI

-

Technology

SBIO

-

XLVI

-

Utilities

SBIO

-

XLVI

-

Financial Services

SBIO
-0.0%
XLVI
100.6%

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

SBIO vs. XLVI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SBIO
SBIO Risk / Return Rank: 7676
Overall Rank
SBIO Sharpe Ratio Rank: 7474
Sharpe Ratio Rank
SBIO Sortino Ratio Rank: 7272
Sortino Ratio Rank
SBIO Omega Ratio Rank: 6363
Omega Ratio Rank
SBIO Calmar Ratio Rank: 9090
Calmar Ratio Rank
SBIO Martin Ratio Rank: 8282
Martin Ratio Rank

XLVI
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SBIO vs. XLVI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ALPS Medical Breakthroughs ETF (SBIO) and State Street Health Care Select Sector SPDR Premium Income ETF (XLVI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


SBIOXLVIDifference
Sharpe ratioReturn per unit of total volatility

Sortino ratioReturn per unit of downside risk

Omega ratioGain probability vs. loss probability

1.38

Calmar ratioReturn relative to maximum drawdown

5.47

Martin ratioReturn relative to average drawdown

16.23

SBIO vs. XLVI - Sharpe Ratio Comparison


Loading charts...

Sharpe Ratios by Period


SBIOXLVIDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

2.35

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.09

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.24

Sharpe Ratio (All Time)

Calculated using the full available price history

0.22

1.54

-1.32

Drawdowns

SBIO vs. XLVI - Drawdown Comparison

The maximum SBIO drawdown since its inception was -63.06%, which is greater than XLVI's maximum drawdown of -8.14%. Use the drawdown chart below to compare losses from any high point for SBIO and XLVI.


Loading charts...

Drawdown Indicators


SBIOXLVIDifference

Max Drawdown

Largest peak-to-trough decline

-63.06%

-8.14%

-54.92%

Max Drawdown (1Y)

Largest decline over 1 year

-12.66%

Max Drawdown (3Y)

Largest decline over 3 years

-42.44%

Max Drawdown (5Y)

Largest decline over 5 years

-53.10%

Max Drawdown (10Y)

Largest decline over 10 years

-63.06%

Current Drawdown

Current decline from peak

-14.84%

-2.08%

-12.76%

Average Drawdown

Average peak-to-trough decline

-28.44%

-1.95%

-26.49%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.26%

Volatility

SBIO vs. XLVI - Volatility Comparison


Loading charts...

Volatility by Period


SBIOXLVIDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.85%

Volatility (6M)

Calculated over the trailing 6-month period

22.76%

Volatility (1Y)

Calculated over the trailing 1-year period

29.40%

11.12%

+18.28%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

33.57%

11.12%

+22.45%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

33.18%

11.12%

+22.06%

SBIO vs. XLVI - Expense Ratio Comparison

SBIO has a 0.50% expense ratio, which is higher than XLVI's 0.35% expense ratio.


Dividends

SBIO vs. XLVI - Dividend Comparison

SBIO has not paid dividends to shareholders, while XLVI's dividend yield for the trailing twelve months is around 11.30%.


PositionTTM202520242023202220212020201920182017
SBIO
ALPS Medical Breakthroughs ETF
0.00%0.00%3.55%0.22%0.00%0.00%0.00%0.04%2.79%1.77%
XLVI
State Street Health Care Select Sector SPDR Premium Income ETF
11.30%5.73%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Frequently Asked Questions


SBIO and XLVI have a correlation of 0.45, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

On fees, XLVI is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.

XLVI is cheaper with a 0.35% expense ratio, compared with 0.50% for SBIO.

XLVI has the higher dividend yield at 11.30%, compared with 0.00% for SBIO.

SBIO is categorized as Health & Biotech Equities, while XLVI is Derivative Income. They also come from different issuers: SS&C and State Street. Their fees differ too: 0.50% for SBIO and 0.35% for XLVI.

Portfolio Optimizer

Find the right allocation for SBIO and XLVI

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer